What’s hot at ACC.24?

Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.

This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24, highlighting their context and relevance for practice.

Trials covered include:
0:42 - IVUS-ACS: Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes
2:22 - Ultimate DAPT: One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes
4:02 - RELIEVE-HF: A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF
6:52 - ORBITA-COSMIC: Coronary Sinus Reducer for the Treatment of Refractory Angina
8:52 -  EMPACT-MI: Empagliflozin After Acute Myocardial Infarction
10:15 - REDUCE-AMI: Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
12:39 - SMART: Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli
14:44 - DEDICATE-DZHK6: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk
16:56 - PERFORM-TAVR: Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement
18:13 - PREVENT: Preventive PCI or Medical Therapy Alone for Atherosclerotic Coronary Vulnerable Plaques
21:32 - FULL REVASC: Ffr-guidance for complete non-culprit REVASCularization
22:46 - DanGer Shock: Danish-German cardiogenic shock trial
25:18 - TARGET BP I: Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs